Further, allografts from subcutaneous injections of Ela-myc tumor–derived cells regressed after sunitinib treatment, suggesting that the complex tumor microenvironment present in the pancreatic niche impairs sunitinib effects in the Ela-myc model (Figure 7). This evidence concerns the gene MYC and neoplasm.